Edwards Lifesciences Cash on Hand 2010-2023 | EW
Edwards Lifesciences cash on hand from 2010 to 2023. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
- Edwards Lifesciences cash on hand for the quarter ending March 31, 2023 was $1.254B, a 16.16% decline year-over-year.
- Edwards Lifesciences cash on hand for 2022 was $1.215B, a 17.15% decline from 2021.
- Edwards Lifesciences cash on hand for 2021 was $1.467B, a 4.58% increase from 2020.
- Edwards Lifesciences cash on hand for 2020 was $1.403B, a 7.54% decline from 2019.
Edwards Lifesciences Annual Cash on Hand
(Millions of US $) |
| 2022 |
$1,215 |
| 2021 |
$1,467 |
| 2020 |
$1,403 |
| 2019 |
$1,517 |
| 2018 |
$957 |
| 2017 |
$1,338 |
| 2016 |
$1,271 |
| 2015 |
$1,225 |
| 2014 |
$1,439 |
| 2013 |
$937 |
| 2012 |
$521 |
| 2011 |
$451 |
| 2010 |
$396 |
| 2009 |
$334 |
Edwards Lifesciences Quarterly Cash on Hand
(Millions of US $) |
| 2023-03-31 |
$1,254 |
| 2022-12-31 |
$1,215 |
| 2022-09-30 |
$1,739 |
| 2022-06-30 |
$1,516 |
| 2022-03-31 |
$1,496 |
| 2021-12-31 |
$1,467 |
| 2021-09-30 |
$1,795 |
| 2021-06-30 |
$1,561 |
| 2021-03-31 |
$1,331 |
| 2020-12-31 |
$1,403 |
| 2020-09-30 |
$1,295 |
| 2020-06-30 |
$1,164 |
| 2020-03-31 |
$1,031 |
| 2019-12-31 |
$1,517 |
| 2019-09-30 |
$1,357 |
| 2019-06-30 |
$934 |
| 2019-03-31 |
$963 |
| 2018-12-31 |
$957 |
| 2018-09-30 |
$1,596 |
| 2018-06-30 |
$1,401 |
| 2018-03-31 |
$1,499 |
| 2017-12-31 |
$1,338 |
| 2017-09-30 |
$1,403 |
| 2017-06-30 |
$1,132 |
| 2017-03-31 |
$918 |
| 2016-12-31 |
$1,271 |
| 2016-09-30 |
$1,200 |
| 2016-06-30 |
$1,060 |
| 2016-03-31 |
$952 |
| 2015-12-31 |
$1,225 |
| 2015-09-30 |
$1,251 |
| 2015-06-30 |
$1,409 |
| 2015-03-31 |
$1,371 |
| 2014-12-31 |
$1,439 |
| 2014-09-30 |
$1,515 |
| 2014-06-30 |
$1,484 |
| 2014-03-31 |
$832 |
| 2013-12-31 |
$937 |
| 2013-09-30 |
$758 |
| 2013-06-30 |
$575 |
| 2013-03-31 |
$558 |
| 2012-12-31 |
$521 |
| 2012-09-30 |
$623 |
| 2012-06-30 |
$506 |
| 2012-03-31 |
$410 |
| 2011-12-31 |
$451 |
| 2011-09-30 |
$451 |
| 2011-06-30 |
$468 |
| 2011-03-31 |
$434 |
| 2010-12-31 |
$396 |
| 2010-09-30 |
$361 |
| 2010-06-30 |
$320 |
| 2010-03-31 |
$321 |
| 2009-12-31 |
$334 |
| 2009-09-30 |
$290 |
| 2009-06-30 |
$188 |
| 2009-03-31 |
$150 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Instruments Manufacturing |
$51.668B |
$5.382B |
|
Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care.
|
